Background and aim: Biosimilar medicines are not considered exact replicas of originator biological medicines. As a result, prescribers can be hesitant to introduce such medicines into the clinical setting until evidence ...
O'Brien, Gary L.; O'Mahony, Denis; Gillespie, Paddy; Mulcahy, Mark; Walshe, Valerie; O'Connor, Marie N.; O'Sullivan, David; Gallagher, James; Byrne, Stephen(Springer International Publishing AG, 2018-07-13)
Background: A recent randomised controlled trial conducted in an Irish University teaching hospital that evaluated a physician-implemented medication screening tool, demonstrated positive outcomes in terms of a reduction ...
The study presented is a comprehensive overview of commercial parenteral protein formulations, approved by the European Medicines Agency (EMA), 1995-2018. The objective of this overview was to analyse current trends in the ...
Khandavilli, Udaya Bhaskara Rao; Skořepová, Eliška; Sinha, Abhijeet S.; Bhogala, Balakrishna R.; Maguire, Nuala M.; Maguire, Anita R.; Lawrence, Simon E.(American Chemical Society, 2018-07-03)
Cocrystallization studies on Naringenin with 27 coformers have led to the formation of five new solid forms: a piperazinium salt (PIP+-NR-) and four cocrystals with the coformers flavone (FLV), 4-hydroxypyridine (4-HP), ...
Cambados, Nadia; Walther, Thomas; Nahmod, Karen; Tocci, Johanna M.; Rubinstein, Natalia; Boehme, Ilka; Simian, Marina; Sampayo, Rocio; Del Valle Suberbordes, Melisa; Kordon, Edith C.; Schere-Levy, Carolina(Impact Journals, 2017)
Angiotensin (Ang) II, the main effector peptide of the renin-angiotensin system, has been implicated in multiple aspects of cancer progression such as proliferation, migration, invasion, angiogenesis and metastasis. ...
This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement